FORT WORTH, Texas, October 9, 2025 – Alcon, the global leader in eye care dedicated to helping people see brilliantly, will showcase product innovations and scientific data at the 2025 American Academy of Ophthalmology (AAO) annual meeting, October 18-20, in Orlando, Florida. Alcon will highlight the inclusion of Valeda^® photobiomodulation (PBM) system into its equipment portfolio, the newly available OnAxis Technology astigmatism management software for the LenSx^® femtosecond laser, as well as the recently launched prescription treatment for the signs and symptoms of dry eye disease, TRYPTYR^® (acoltremon ophthalmic solution) 0.003%. Additionally, Alcon will present data demonstrating its commitment to providing high-quality, innovative products to customers.^4-6 Ophthalmologists, surgical staff, researchers, and industry leaders can visit Alcon at booth #2120 for hands-on demonstrations and engaging experiences.

“This year marks a defining moment for Alcon. From the launches of UNITY^® VCS|CS, PanOptix^® Pro and TRYPTYR to the integration of Valeda PBM, we’ve introduced significant technology across nearly every ophthalmic specialty we support,” said Sergio Duplan, Alcon Senior Vice President, President, Americas. “AAO 2025 is an opportunity to show how these innovations are impacting clinical practice, empowering surgeons, and shaping the future of eye care.”

AAO 2025 rounds out an unprecedented year of innovation at Alcon. Alcon's combined vitreoretinal and cataract system, UNITY VCS|CS, will be prominently featured at this year’s conference, as will other Alcon innovations launched in 2025. The system, which is designed to deliver superior efficiency^*, features over a dozen first-to-market technologies.^7-12,*,** Attendees can demo both configurations, the combined console UNITY^® VCS, and the standalone cataract system, UNITY^® CS. Also released this year, Clareon^® PanOptix^® Pro, Voyager^® DSLT, wavelight plus, and Adi will be available at the Alcon booth.

Dry age-related macular degeneration (AMD) innovation on display. Alcon recently expanded its retina portfolio with the addition of Valeda PBM in its acquisition of LumiThera. The Valeda PBM, the first and only FDA-approved light therapy to demonstrate visual improvement in patients with dry AMD at two years, will also be available for in-booth demos.^1,2

For the first time, Alcon’s LenSx femtosecond laser, trusted by surgeons and proven in more than 4.5 million cases worldwide, will include new OnAxis Technology for complete astigmatism management.¹³ These new, advanced features include:

• Capsular toric markings: Permanent demarcations on the capsule enabling precise toric IOL alignment and post-surgery verification of rotational stability³
• The LaserArcs nomogram significantly reduces astigmatism in patients undergoing FLACS with arcuate incisions.^14***
• Advanced fragmentation patterns: Designed to assist surgeons with their phaco technique allowing for a customizable size and shape of the fragmentation of the lens³

LenSx with OnAxis Technology is now available to U.S.-based customers and demos will be available at the Alcon booth.

In addition to surgical innovation, Alcon recently announced the U.S. availability of TRYPTYR, a new prescription treatment option available to the millions of patients affected by Dry Eye Disease (DED). TRYPTYR is the first neuromodulator eye drop to rapidly increase natural tear production as early as day one.^15-19 More information about this novel therapy will be on display at the Alcon booth, with further details about Alcon’s full portfolio of pharmaceutical products available at https://www.myalcon.com/prescription-drugs/.

Alcon will highlight scientific data on TRYPTYR, Clareon PanOptix Pro and wavelight plus, as well as several of its industry-leading surgical products. These studies include:

• Results from a Pooled Analysis of Phase 3 Studies of Subjects Treated with Acoltremon 0.003%, presented by David Wirta, MD as a Scientific Poster.⁴
• ”A Real-World, Prospective, Comparative Study of Post-Operative Chair Time for Advanced Technology Intraocular Lenses,” presented by Satish Modi, MD as a Scientific Poster.⁵
• “Ray Tracing LASIK (wavelight plus) vs. SMILE for Myopia Correction: A Randomized, Prospective, Contralateral Eye Study,” presented by John Kanellopoulos on Saturday, October 20, at 12:30 PM in Room #W314.⁶

Additional educational opportunities and experiences for Eye Care Professionals will be available at the Alcon booth. For more about the Alcon products, services and scientific data that will be available at the 2025 American Academy of Ophthalmology, please visit MyAlconatAAO.com.

###

*Based on bench testing
**Compared to CENTURION and CONSTELLATION Vision Systems. Based on bench data.
*** Mean reduction 81.4 ± 47.7%; 95%CI 67.7%–94.3%; p<0.00001

About Alcon

Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning over 75 years, we offer the broadest portfolio of products to enhance sight and improve people’s lives. Our Surgical and Vision Care products touch the lives of more than 260 million people in over 140 countries each year living with conditions like cataracts, glaucoma, retinal diseases and refractive errors. Our more than 25,000 associates are enhancing the quality of life through innovative products, partnerships with Eye Care Professionals and programs that advance access to quality eye care. Learn more at www.alcon.com.

About TRYPTYR® (acoltremon ophthalmic solution) 0.003% 

INDICATIONS AND USAGE
TRYPTYR^® (acoltremon ophthalmic solution) 0.003% is indicated for the treatment of the signs and symptoms of dry eye disease (DED).
IMPORTANT SAFETY INFORMATION
Warnings and Precautions
Potential for Eye Injury and Contamination: To avoid the potential for eye injury and contamination, advise patients not to touch the vial tip to the eye or other surfaces.
Use with Contact Lenses: TRYPTYR should not be administered while wearing contact lenses. If contact lenses are worn, they should be removed prior to administration of the solution. Lenses may be reinserted 15 minutes following administration of TRYPTYR.
Adverse Reactions
In clinical trials, the most common adverse reaction was instillation site pain (50%).

Please click here for the TRYPTYR Full Prescribing Information

About Valeda^® PBM

The Valeda Light Delivery System improves visual acuity in patients with best-corrected visual acuity of 20/32 through 20/70 and who have dry age-related macular degeneration (AMD) characterized by: 1. The presence of at least 3 medium drusen (> 63 μm and ≤ 125 μm in diameter), or large drusen (> 125 μm in diameter), or non-central geographic atrophy, and 2. The absence of neovascular maculopathy or central-involving geographic atrophy. Do not treat patients with Valeda if they have any known photosensitivity to yellow light, red light, or near-infrared radiation (NIR), have a history of light-activated central nervous system disorders (e.g., epilepsy, migraine), or within 30 days of using photosensitizing agents. Treatment benefit may not persist significantly after treatment is stopped. No significant data on the safety and effectiveness for more frequent or extended treatments beyond described in operator’s manual.

About LenSx^®

The LenSx Laser system is indicated for use: In the creation of corneal cuts/incisions (single-plane, multiplane, and arcuate), anterior capsulotomy and laser phacofragmentation during cataract surgery. Each of these procedures may be performed either individually or consecutively during the same surgery. In the creation of corneal cuts/incisions (single-plane, multiplane, and arcuate) during Implantable Collamer Lens (ICL) surgery. In the creation of a corneal flap in patients undergoing LASIK surgery or other treatment requiring initial lamellar resection of the cornea. In the creation of corneal pockets for placement/insertion of a corneal inlay device; and for creation of corneal tunnels for the placement of corneal rings. Refer to the LenSx Operator’s Manual for a complete listing of indications, warnings, cautions and notes.

About UNITY^® VCS and CS

The UNITY^® VCS (Vitreoretinal Cataract System) console, when used with compatible devices, is indicated for use during anterior segment (i.e., phacoemulsification and removal of cataracts) and posterior segment (i.e., vitreoretinal) ophthalmic surgery. In addition, with the optional laser, this system is indicated for photocoagulation (i.e., vitreoretinal and macular pathologies), iridotomy and trabeculoplasty procedures. The UNITY^® CS (Cataract System) console, when used with compatible devices, is indicated for use during anterior segment (i.e., phacoemulsification and removal of cataracts) ophthalmic surgery. Refer to the Directions for Use for the accessories/consumables and User Manual for a complete listing of indications, warnings, cautions and notes.

UNITY^® VCS and CS Important Product Information
Caution: Federal (USA) law restricts this device to sale by, or on the order of, a 
physician. 
Indications / Intended Use: 
UNITY VCS: 
The UNITY VCS console, when used with compatible devices, is indicated for use during anterior segment (i.e. phacoemulsification and removal of cataracts) and posterior segment (i.e. vitreoretinal) ophthalmic surgery. 
In addition, with the optional laser this system is indicated for photocoagulation (i.e. vitreoretinal and macular pathologies), iridotomy and trabeculoplasty procedures. 
UNITY CS: 
The UNITY CS console, when used with compatible devices, is indicated for use during anterior segment (i.e. phacoemulsification and removal of cataracts) ophthalmic surgery. 
Warnings: 
Appropriate use of UNITY VCS and CS parameters and accessories is important for successful procedures. The console supports various accessories to perform various surgical procedures. Accessories include handpieces and probes, as well as tips and sleeves when necessary. Different accessories are required for different procedures and operating modes. 
Test for adequate irrigation and aspiration flow, reflux, and operation of each accessory prior to entering the eye. 
The consumables used in conjunction with ALCON^® instrument products constitute a complete surgical system. To avoid the risk of a patient hazard, do not mismatch consumable components or use settings not specifically adjusted for particular consumable component combinations. 
AEs/Complications: 
Inadvertent activation of functions that are intended for priming or tuning accessories while the accessory is in the eye can create a hazardous situation that could result in patient injury. During any ultrasonic procedure, metal particles may result from inadvertent touching of the ultrasonic tip with a second instrument. Another potential source of metal particles resulting from any ultrasonic handpiece may be the result of ultrasonic energy causing micro abrasion of the ultrasonic tip. 
ATTENTION: 
Refer to the Directions for Use for the accessories/consumables and User Manual for a complete listing of indications, warnings, cautions and notes.

About Clareon^® PanOptix^® Pro

The Clareon PanOptix Pro Trifocal IOL is a type of multifocal IOL used to focus images clearly onto the back of your eye (retina) to allow clear vision after the cataract removal. In addition, the center of the Clareon PanOptix Pro Trifocal IOL allows for better near (reading) vision and intermediate (computer work) vision versus what a monofocal lens would provide.
Potential Side Effects: Due to the design of multifocal IOLs, there are some side effects that can be associated with the Clareon PanOptix Pro Trifocal IOL models. These may be worse than with a monofocal IOL, including visual disturbances such as glare, rings around lights, starbursts (rays around light sources), and reduced contrast sensitivity (decreased ability to distinguish objects from their background, especially in dim lighting). These side effects may make it more difficult to see while driving at night or completing tasks in low lighting conditions such as at night or in fog or in a dimly lit room after surgery, as compared to before surgery.

About wavelight plus 

The wavelight femtosecond and excimer laser systems are medical devices that are indicated for use in performing laser-assisted in-situ keratomileusis (LASIK) and photorefractive keratectomy (PRK) procedures to correct certain kinds of nearsightedness (myopia), farsightedness (hyperopia), and astigmatism. The INNOVEYES™ Sightmap is indicated for screening and diagnosis of adult patients who may undergo a customized photorefractive treatment with the wavelight laser systems. Only doctors who are well versed in its diagnostic abilities and possible dangers should use wavelight technology. The most common risks of refractive laser vision correction surgery include dry eye syndrome; the possible need for glasses or contact lenses after surgery; visual symptoms including halos, glare, starbursts, and double vision; and loss of vision.

References

1. U.S. Food and Drug Administration. De Novo classification request for Valeda Light Delivery System (DEN230083). Accessed June 2025 at https://www.accessdata.fda.gov/cdrh_docs/pdf23/DEN230083.pdf.
2. LumiThera, Inc. A double-masked, randomized, sham-controlled, parallel group, multi-center study to assess the safety and efficacy of photobiomodulation (PBM) in subjects with dry age-related macular degeneration (AMD) (LIGHTSITE III). Clinical Study Report CSP005.
3. Alcon Data on File, 2024. REF-25676.
4. Wirta D., et al. A High Percentage of Subjects Treated with Acoltremon 0.003% Achieve Normal Tear Production: Results from Pooled Analysis of Phase 3 Studies. To be presented at: American Academy of Ophthalmology Annual Meeting; October 2025; Orlando.
5. Modi S., et al. A Real-World, Prospective, Comparative Study of Post-Operative Chair Time for Advanced Technology Intraocular Lenses. To be presented at: American Academy of Ophthalmology Annual Meeting; October 2025; Orlando.
6. Kanellopoulos J., et al. Ray Tracing LASIK (wavelight plus) vs. SMILE for Myopia Correction: A Randomized, Prospective, Contralateral Eye Study. To be presented at: American Academy of Ophthalmology Annual Meeting; October 2025; Orlando.
7. Alcon Data on File, 2024. REF-24644.
8. Alcon Data on File, 2024. REF-24615.
9. Alcon Data on File, 2024. REF-24379.
10. Alcon Data on File, 2024. REF-24576.
11. UNITY Phaco Handpiece Directions for Use.
12. UNITY VCS and CS User Manual.
13. Alcon Data on File, 2025. REF-27019
14. Jones M, Hovanesian JA, Keyser A. Accuracy of the LaserArcs femtosecond cataract surgery arcuate incision nomogram in patients undergoing cataract surgery and astigmatism reduction. Clin Ophthalmol 2023:17 681–689.
15. TRYPTYR® U.S. FDA Prescribing Information. 2025.
16. Restasis. Prescribing Information. Allergan; 2012. Accessed July 8, 2024. https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/050790s020lbl.pdf.
17. Xiidra. Prescribing Information. Bausch & Lomb; 2020. Accessed September 10, 2025. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208073s005lbl.pdf
18. Tyrvaya. Prescribing Information. Oyster Point Pharmaceuticals; 2024. Accessed January 16, 2025. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213978s000lbl.pdf
19. Miebo. Prescribing Information. Bausch & Lomb; 2023. Accessed June 26, 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216675s000lbl.pdf

Connect with us on Facebook and LinkedIn 

Media Relations

Kevin Nicoletti
+ 1 817 913 3461 (Fort Worth)
[email protected]

Investor Relations

Allen Trang
+ 41 589 112 110 (Geneva)

Daniel Cravens
+ 1 817 615 2789 (Fort Worth)
[email protected]